Atea Pharmaceuticals, Inc.

  • Earnings Score
  • Market Cap $257.65M
  • PE -1
  • Debt $NaN
  • Cash $98.46M
  • EV $NaN
  • FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$174.01M
EBIT-$172.96M
ROE-38%
ROA-35%
Equity$458.52M
Growth Stability-361%
PE-1.48
PEG-24.73
PB0.56
Price/Cash0.38
Earnings CAGR0%
Equity CAGR-4%
Earnings Stability-0.56
Earnings Growth YoY-6%
Earnings Growth QoQ-23%
Earnings CAGR 5Y0%
Equity CAGR 5Y-6%
Equity CAGR 3Y-14%
Market Cap$257.65M
Assets$490.96M
Cash$98.46M
Shares Outstanding84.2M
Earnings Score6%
Working Capital461.72M
Current Ratio19.33
Shares Growth 3y0%
Equity Growth QoQ-4%
Equity Growth YoY-21%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.

SEC Filings

Direct access to Atea Pharmaceuticals, Inc. (AVIR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Atea Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Atea Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%
Stability -56%
loading chart...

Atea Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Atea Pharmaceuticals, Inc..

0
012345678910TV
fcf$0$0$0$0$0$0$0$0$0$0$0$0
DCF$0$0$0$0$0$0$0$0$0$0$0
Value$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201812/201912/202012/202112/202212/2023TTM
Net Margins---23%34%---
ROA--64%-1%18%-18%-23%-35%
ROE-28%-2%17%-18%-24%-38%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-------
Debt over Equity-------
Growth Stability-----361%--361%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth---622%---
Earnings YoY growth-55%-22%-1K%-196%17%0%
Equity YoY growth-37%-1K%30%-10%-13%-6%
FCF YoY growth-62%-2K%-129%41%--